Biomarin Pharmaceutical Inc Dossier
Qualitative Analysis
Business overview
BioMarin Pharmaceutical Inc. is a global biotechnology company dedicated to developing and commercializing innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The company's commercial portfolio includes enzyme replacement therapies and genetic medicines such as VOXZOGO (vosoritide) for achondroplasia, VIMIZIM, NAGLAZYME, PALYNZIQ, BRINEURA, and ALDURAZYME. BioMarin has established a commercial presence in over 80 countries, leveraging world-class capabilities in molecular biology, manufacturing, and global regulatory affairs to address the root causes of genetic disorders.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A comprehensive operational restructuring program initiated in September 2024 designed to streamline ways of working, optimize the organizational model, and eliminate redundancies.
Expected impact: Aims to deliver $500 million in cost benefits by 2026, supporting the company's target of achieving a 40% Non-GAAP operating margin.
Aggressive commercial expansion of VOXZOGO (vosoritide) for achondroplasia into new geographic markets and clinical indications.
Expected impact: Expands geographic reach from 49 countries in early 2025 to over 60 by 2027, driving VOXZOGO revenues toward blockbuster status (projected at $975 million to $1.025 billion for 2026).
Voluntary withdrawal of the gene therapy ROCTAVIAN from the market in February 2026 following commercial underperformance and unsuccessful efforts to divest the asset.
Expected impact: Eliminates ongoing commercialization expenses and allows the company to reallocate resources to high-growth enzyme therapies and skeletal conditions.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To strengthen and diversify BioMarin's commercial rare disease portfolio by adding Galafold (for Fabry disease) and Pombiliti + Opfolda (for Pompe disease), leveraging BioMarin's global scale and manufacturing capabilities.
Financial impact: Expected to add over $600 million in high-growth revenue, slightly dilutive to 2026 Non-GAAP EPS but projected to be accretive starting in 2027.
To bolster BioMarin's enzyme therapies pipeline by acquiring INZ-701 (BMN 401), a late-stage enzyme replacement therapy being developed for ENPP1 Deficiency.
Financial impact: Added a late-stage clinical asset with potential regulatory filing and launch, though H1 2026 Phase 3 data showed mixed results.
Strategic Partnerships
To accelerate the development and commercialization of rare disease therapies by leveraging Veeva's cloud-based software, data, services, and consulting products.
Terms: Financial terms were not disclosed.
Acquired the U.S. commercial licensing rights to DMX-200 (a Phase 3 investigational small molecule for focal segmental glomerulosclerosis) as part of the Amicus Therapeutics acquisition.
Terms: Dimerix remains eligible to receive up to $590 million in upfront, development, and sales milestones, plus tiered low-teen to low-twenties royalties on net sales.